SkinBioTherapeutics PLC
LSE:SBTX
SkinBioTherapeutics PLC
LSE:SBTX
Price:
9.75
GBX
Market Closed
Market Cap:
£25.3m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
SkinBioTherapeutics PLC
LSE:SBTX
|
UK |
|
Toa Road Corp
TSE:1882
|
JP |
|
E
|
Easyjet PLC
OTC:ESYJY
|
UK |
|
Indusind Bank Ltd
BSE:532187
|
IN |
|
Changzhou Tenglong Auto Parts Co Ltd
SSE:603158
|
CN |
|
Cauldron Energy Ltd
ASX:CXU
|
AU |
|
L
|
Left Field Printing Group Ltd
HKEX:1540
|
HK |
|
I
|
Inbest Prime II Inmuebles SOCIMI SA
MAD:YINB2
|
ES |
|
C
|
CMC JSC
VN:CVT
|
VN |
|
Superkrane Mitra Utama Tbk PT
IDX:SKRN
|
ID |
|
Shree Ganesh Remedies Ltd
BSE:540737
|
IN |
|
G
|
Garuda Indonesia (Persero) Tbk PT
XBER:YGD
|
ID |
|
Hensoldt AG
XETRA:HAG
|
DE |
Income Statement
Earnings Waterfall
SkinBioTherapeutics PLC
SkinBioTherapeutics PLC
Income Statement
SkinBioTherapeutics PLC
SkinBioTherapeutics PLC
Currency: GBP
| Dec-2018 | Jun-2019 | Dec-2019 | Jun-2020 | Dec-2020 | Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||
| Interest Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
+240%
|
0
+74%
|
0
+2%
|
0
+22%
|
1
+648%
|
3
+122%
|
5
+73%
|
|
| Gross Profit | |||||||||||||||
| Cost of Revenue |
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(1)
|
(1)
|
(2)
|
|
| Gross Profit |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
+238%
|
0
+85%
|
0
+2%
|
0
+19%
|
1
+572%
|
1
+119%
|
3
+92%
|
|
| Operating Income | |||||||||||||||
| Operating Expenses |
(1)
|
(1)
|
(2)
|
(2)
|
(1)
|
(1)
|
(2)
|
(3)
|
(3)
|
(3)
|
(3)
|
(4)
|
(4)
|
(4)
|
|
| Selling, General & Administrative |
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Research & Development |
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
|
| Other Operating Expenses |
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(1)
|
(2)
|
(2)
|
(2)
|
(2)
|
(3)
|
(3)
|
(4)
|
|
| Operating Income |
(1)
N/A
|
(1)
-15%
|
(2)
-19%
|
(2)
0%
|
(1)
+16%
|
(1)
-10%
|
(2)
-35%
|
(3)
-47%
|
(3)
-6%
|
(3)
+6%
|
(3)
-1%
|
(3)
+4%
|
(3)
+12%
|
(1)
+56%
|
|
| Pre-Tax Income | |||||||||||||||
| Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
0
|
0
|
|
| Pre-Tax Income |
(1)
N/A
|
(1)
-15%
|
(2)
-19%
|
(2)
0%
|
(1)
+16%
|
(1)
-10%
|
(2)
-36%
|
(3)
-47%
|
(3)
-6%
|
(3)
+6%
|
(3)
-1%
|
(3)
+3%
|
(3)
+12%
|
(1)
+72%
|
|
| Net Income | |||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(1)
|
(1)
|
(1)
|
(2)
|
(1)
|
(1)
|
(2)
|
(3)
|
(3)
|
(3)
|
(3)
|
(3)
|
(3)
|
(1)
|
|
| Net Income (Common) |
(1)
N/A
|
(1)
-11%
|
(1)
-25%
|
(2)
-4%
|
(1)
+16%
|
(1)
-14%
|
(2)
-34%
|
(3)
-45%
|
(3)
-8%
|
(3)
+6%
|
(3)
-2%
|
(3)
+0%
|
(3)
+10%
|
(1)
+73%
|
|
| EPS (Diluted) |
-0.01
N/A
|
-0.01
N/A
|
-0.01
N/A
|
-0.01
N/A
|
-0.01
N/A
|
-0.01
N/A
|
-0.01
N/A
|
-0.02
-100%
|
-0.02
N/A
|
-0.02
N/A
|
-0.02
N/A
|
-0.02
N/A
|
-0.01
+50%
|
0
N/A
|
|
Switch to:
Switch to:
See Also
Discover More
